The characterization of a humanized rabbit anti-TNF α monoclonal antibody?A nationwide RA treatment drug study
wang, c.; Ni, x.; Liu, y.; Jin, z.; Xia, h.; N/A,
Show abstract
Tumor necrosis factor alpha (TNF) is now regarding as a key role in the pathogenesis of immune-mediated disease such as Rheumatoid arthritis (RA), Crohn's Disease, Psoriatic arthritis and Plaque Psoriasis. HERE we have successfully developed an anti-hTNF monoclonal rabbit antibody(HZ3M) with high binding and neutralizing activity based on RabMAbs platform. Rabbit hybridomas, immunized subcutanrously with 0.4 mg human TNF, were generated from the rabbit splenocytes and a total of 142 hybridoma clones with specific binding to human TNFa were obtained. The anti-TNFa RabMAbs showed better neutralizing activity and higher antigen binding affinity compared to Humira and Remicade, the elimination phase half-life 58.2h respectively. In vivo efficay studies, normal mice or human TNF-alpha transgenic mice were injected with 1.0 mg/kg Humira (positive control), HZ3M at 0.33?1.0 or 3.0 mg/kg, or solvent (negative control), showed that HZ3M is able to bind and neutralize hTNF in transgenic and normal mice as well as normal rabbits.Clearly dose-dependent response can be determined. Compared to marketed anti-TNFa drug Humira, the efficacy of HZ3M is seems to show significant longer holding time.Our observations indicate that the HZ3M derived from RabMAb preclinical safety study, and might have a therapeutic role in RA treatment.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Fast in-vitro screening of FLT3-ITD inhibitors using silkworm-baculovirus protein expression system 95%
- In silico analysis and in planta production of recombinant ccl21/IL1β protein and characterization of its in vitro anti-tumor and immunogenic activity 95%
- Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches 94%
Similar papers in this journal
- Novel Peptide Inhibitor of Human Tumor Necrosis Factor-α has Antiarthritic Activity 96%
- Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice 94%
- In silico tool for Predicting, Designing and Scanning IL-2 inducing peptides 93%
Similar papers in this journal
- The mitochondrial deubiquitinase USP30 regulates AKT/mTOR signaling 94%
- Development of a Novel Bruton's Tyrosine Kinase Inhibitor that exerts Anti-Cancer Activities Potentiates Response of Chemotherapeutic Agents In Multiple Myeloma Stem Cell-Like Cells 94%
- Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19 94%
Similar papers in this journal
- Contriving a chimeric polyvalent vaccine to prevent infections caused by Herpes Simplex Virus (Type-1 and Type-2): an exploratory immunoinformatic approach 94%
- Computationally validated SARS-CoV-2 CTL and HTL Multi-Patch Vaccines designed by reverse epitomics approach, shows potential to cover large ethnically distributed human population worldwide 94%
- Molecular Elucidation of Pancreatic Elastase Inhibition by Baicalein 94%
Similar papers in this journal
- Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2 94%
- RIG-I has a role in immunity against Haemonchus contortus, a gastrointestinal parasite in Ovis aries- a novel report. 93%
- Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis. 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.